Announcements
- Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
- Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
- Matinas BioPharma Prices $10 Million Registered Direct Offering
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
More ▼
Key statistics
As of last trade, Matinas BioPharma Holdings Inc (6LJ:MUN) traded at 0.1504, 34.29% above the 52 week low of 0.112 set on Oct 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1504 |
---|---|
High | 0.1504 |
Low | 0.1504 |
Bid | 0.1437 |
Offer | 0.1512 |
Previous close | 0.1504 |
Average volume | 444.44 |
---|---|
Shares outstanding | 250.82m |
Free float | 244.48m |
P/E (TTM) | -- |
Market cap | 40.18m USD |
EPS (TTM) | -0.107 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 07:03 BST.
More ▼